1Kaplan NM,Opie L.Controversies in hypertension[J].Lancet,2006,367:168-176.
2Casas JP,Chua Weiliang,Loukogeorgakis S,et al.effect of inhibitors of the rennin-angiotensin system and other antihypertensive drugs on renal outcomes:systematic review and meta-analysis[J].Lancet,2005,366:2026-2033.
3McDonald MA,Simpson SH,Ezekowitz JA,et al.Angiotensin receptor blockers and risk of myocardial infarction:systematic review[J].BMJ,2005,331:873-878.
4Doulton TW,He F J,MacGregor GA.Systematic review of combined angiotensin-converting enzyme in hibition and angiotensin receptor blockade in hypertension[J].Hypertension,2005,45 (5):880-886.
5Strippoli GF,Craig M,Schena FP,et al.Antihy pertensive agents for primary prevention of diabetic nephropathy[J].Am Soc Nephrol,2005,16 (10):3081-3091.
6Epstein B J,Gums JG.Can the renin-angiotensin sys tem protect against stroke? A focus on angiotensin Ⅱ receptor blockers[J].Pharmacotherapy,2005,25(4):531-539.
7Verma S,Strauss M.Andiotensin receptor blockers and myocardial infarction[J].BMJ,2004,329:1248-1249.
8Strippoli GF,Craig M,Deeks JJ,et al.Effects of angiotensin converting enzyme inhibitors and agiotensin Ⅱ receptor antagonists on mortality and renal out comes in diabetic nephropathy:systematic review[J].BMJ,2004,329:828-838.
9Engelhorn T,Goerike S,Doerfler A,et al.The an giotensin Ⅱ type 1-receptor blocker candesartan in creases cerebral blood flow,reduces infarct size,and improves neurologic outcome after transient cerebral ischemia in rats[J].J Cereb Blood Flow Metab,2004,24 (4):467-474.
1Pitt B,Segal R.Martinez FA,et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).Lancet, 1997,349:747-752.
2Pitt B,Poole-Wilson PA,Segal R,et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.Lancet, 2000,355:1582-1587.
3Daholof B,Devereux RB,Kjeldsen SE,et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.Lancet,2002,359:995-1003.
4Lewis EJ,Hunsicker LG,Clarke WR,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.N Engl J Med, 2001,345:851-860.
5Circulation, 2002;106:672.
6Parving HH,Lehnert H,Brochner-Mortensen J,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.N Engl J Med, 2001,345:870-878.
7Brenner BM,Cooper ME,de Zeeuw D,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.N Engl J Med. 2001 Sep 20;345(12):861-869.
8Lithell H,Hansson L,Skoog I,et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.J Hypertens, 2003,21:875-886.
9ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Groop. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lo
10Wong M,Staszewsky L,Latini R,et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.J Am Coll Cardiol, 2002,40:970-975.
2Duncia J V, Chiu A T, Carini D J, et al. The discovery of potent nonpeptide angiotensin Ⅱ receptor antagonists: a new class of potent antihypertensives[J]. J Med Chem, 1990, 33(5) : 1 312-1 329.
3Wexler R R, Greenlee W J, Irvin J D, et al. Nonpeptide angiotensin Ⅱ receptor antagonists: The next generation in antihypertensive therapy[J]. J Med Chem, 1996, 39(3) : 625-656.
4de Gasparo M, Catt K J , Inagami T, etal. International union of pharmacology. XXIII. The angiotensin Ⅱ receptors[J]. Pharmacol Rev, 2000, 52(3): 415-472.
5Zoumpoulakis P, Politi A, Grdadolnik S G, et al. Structure elucidation and conformational study of V8 :A novel synthetic non peptide AT1 antagonist[J]. J Pharm Biomed Anal, 2006, 40:1 097-1 104.
6Zoumpoulakis P, Zoga A, Roumelioti P, et al. Conformational and biological studies for a pair of novel synthetic AT(1) antagonists: stereoelectronic requirements for antihypertensive efficacy[J]. J Pharm Biomed Anal, 2003, 31(5) : 833-844.
7Frisch M J, Trucks G W, Schlegel H B, et al. Gaussian 03[CP]B. 05 edit. Gaussian Inc Pittsburgh PA. 2003.
8Mavromoustakos T, Kolocouris A, Zervou M, et al. An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations[J]. J Med Chem, 1999, 42 (10) : 1 714- 1 722.
9Zoumpoulakis P, Grdadolnik S G, Matsoukas J, et al. Structure elucidation and conformational properties of eprosartan a non peptide Angiotensin Ⅱ AT(1) antagonist[J]. J Pharm Biomed Anal, 2002, 28(1) : 125-135.
